Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082654
PUBLISHER: DelveInsight | PRODUCT CODE: 2082654
Metastatic HR+/HER2- Breast Cancer - Epidemiology Forecast - 2036
PUBLISHED:
PAGES: 176 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Metastatic HR+/HER2- Breast Cancer Insights and Trends
- Breast cancer is a genetically and clinically heterogeneous disease with multiple subtypes. The HR+/HER2- subtype is the most common of all the breast cancer subtypes.
- In the US, from the mid-2000s, invasive breast cancer in women has increased by ~0.5% each year. This is likely caused by an increase in excess body weight in women overall, as well as a drop in fertility rates and a rise in age for first births. However, as per the reports from the American Cancer Society, breast cancer cases have increased with a significant CAGR from 2019 to 2023.
- The incidence of breast cancer in Germany is expected to rise in the future, primarily because of the aging population and shifts in reproductive patterns. These shifts encompass a greater number of women without children, delayed first-time motherhood, reduced breastfeeding rates, and lifestyle modifications, encompassing dietary and exercise habits.
- In France, the incidence of invasive breast cancer increased annually by ~0.8% in all age groups combined from 1990 to 2018.
- In the UK, breast cancer incidence rates in females have increased by around 24% from 2016 to 2018. However, these incidence rates are projected to rise by less than 1% in the UK between 2023-2025 and 2038-2040.
- In Japan, there is a marked and ongoing increase in the incidence of breast cancer. While the specific reasons for this rise remain uncertain, it is well-established that female hormones play a pivotal role in the development and growth of breast cancer. Additionally, the genetic background of individuals is closely intertwined with the susceptibility to this disease.
Metastatic HR+/HER2- Breast Cancer Epidemiology Forecast in the US
- 2025 Incident Cases of Metastatic HR+/HER2- Breast Cancer (The US): ~ 57,000
- Metastatic HR+/HER2- Breast Cancer Growth Rate (2026-2036): ~ 1% CAGR
DelveInsight's 'Metastatic HR+/HER2- Breast Cancer - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the metastatic HR+/HER2- breast cancer, historical and forecasted epidemiology of the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.
Metastatic HR+/HER2- Breast Cancer Understanding and Diagnosis Algorithm
Metastatic HR+/HER2- Breast Cancer Overview and Diagnosis
HR+/HER2- breast cancer is the most common subtype of breast cancer, characterized by cancer cells with hormone receptors for estrogen and progesterone but lacking the overexpression of HER2. This subtype generally has a better prognosis and is often treated with hormone therapy to block hormone-driven growth. Surgery and radiation may be used to remove or target tumors, while chemotherapy and targeted therapies like CDK4/6 inhibitors may be considered for more advanced cases. Early detection is crucial, and support from healthcare providers and loved ones is vital for coping with the diagnosis of HR+/HER2- breast cancer. A biopsy confirms the diagnosis and determines the cancer's characteristics. Staging tests assess the cancer's extent, guiding a multidisciplinary team in devising a personalized treatment plan. Emotional support plays a crucial role in managing the emotional toll of the diagnosis, and follow-up care ensures ongoing monitoring and adjustment of treatment as needed, fostering hope for successful recovery and survivorship.
Metastatic HR+/HER2- Breast Cancer Epidemiology
Key Findings from Metastatic HR+/HER2- Breast Cancer Epidemiological Analysis and Forecast
- According to the estimates, the total incident population of HR+/HER2- breast cancer in the 7MM was nearly 486,000 cases in 2025. The cases in the 7MM are expected to increase during the forecast period, i.e., 2026-2036.
- The metastatic HR+/HER2- breast cancer cases were highest in the United States, accounting for ~57,000 cases in 2025.
- According to the estimates, most cases of HR+/HER2- breast cancer occur in people aged between 60 and 79 years in the United States, accounting for ~48% of cases in 2025.
- Among EU4 and the UK, Germany had the maximum total incident cases of HR+/HER2- breast cancer, with ~50,500 cases in 2025, while Spain accounted for the least number of incident cases.
Scope of the Report:
- The report covers a segment of a descriptive overview of metastatic HR+/HER2- breast cancer, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Metastatic HR+/HER2- Breast Cancer Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) bottom-up forecasting
- 11-year forecast
- Patient Burden trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of metastatic HR+/HER2- breast cancer? What will be the growth opportunities across the 7MM concerning the patient population with metastatic HR+/HER2- breast cancer?
- What is the historical and forecasted metastatic HR+/HER2- breast cancer patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
- Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI0908
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Metastatic HR+/HER2- Breast Cancer
4. Epidemiology Forecast Methodology
5. Disease Background and Overview of Metastatic HR+/HER2- Breast Cancer
- 5.1. Introduction
- 5.2. Types of Breast Cancer
- 5.2.1. Subtypes of Breast Cancer
- 5.2.2. Molecular Subtypes of Breast Cancer
- 5.3. Estrogen Receptor (ER)-Positive Breast Cancer
- 5.3.1. Estrogen Receptor
- 5.3.2. Estrogen Receptor 1 Mutations
- 5.4. Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer
- 5.4.1. Role of Estrogen Receptor Alpha (ERa) in Regulating Breast Cancer Metabolism
- 5.5. Symptoms of HR-Positive Breast Cancer
- 5.6. Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer
- 5.7. Characterization of HER2-low Breast Cancers
- 5.7.1. Biology of HER2-low Breast Cancer
- 5.8. Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer
- 5.9. Diagnostic Guidelines
- 5.9.1. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update 2020
- 5.9.2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
6. Epidemiology and Patient Population of Metastatic HR+/HER2- Breast Cancer
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.3. Total Incident Cases of Breast Cancer in the 7MM
- 6.4. Total Incident Cases of HR+/HER2- Breast Cancer in the 7MM
- 6.5. The United States
- 6.5.1. Total Incident Cases of Breast Cancer in the United States
- 6.5.2. Incidence of HR+/HER2- Breast Cancer in the United States
- 6.5.3. Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in the United States
- 6.5.4. Stage-specific Incidence of HR+/HER2- Breast Cancer in the United States
- 6.5.5. Age-specific Incidence of HR+/HER2- Breast Cancer in the United States
- 6.5.6. Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in the United States
- 6.6. EU4 and the UK
- 6.6.1. Total Incidence of Breast Cancer in EU4 and the UK
- 6.6.2. Incidence of HR+/HER2- Breast Cancer in EU4 and the UK
- 6.6.3. Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in EU4 and the UK
- 6.6.4. Stage-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK
- 6.6.5. Age-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK
- 6.6.6. Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in EU4 and the UK
- 6.7. Japan
- 6.7.1. Total Incidence of Breast Cancer in Japan
- 6.7.2. Incidence of HR+/HER2- Breast Cancer in Japan
- 6.7.3. Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in Japan
- 6.7.4. Stage-specific Incidence of HR+/HER2- Breast Cancer in Japan
- 6.7.5. Age-specific Incidence of HR+/HER2- Breast Cancer in Japan
- 6.7.6. Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in Japan
7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Product Code: DIEI0908
List of Tables
- Table 1: Summary of HR+/HER2- Breast Cancer Epidemiology (2022-2036)
- Table 2: Total Incident Cases of Breast Cancer in the 7MM (2022-2036)
- Table 3: Total Incident Cases of HR+/HER2- Breast Cancer in the 7MM (2022-2036)
- Table 4: Total Incident Cases of Breast Cancer in the United States (2022-2036)
- Table 5: Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Table 6: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in the United States (2022-2036)
- Table 7: Stage-specific Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Table 8: Age-specific Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Table 9: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Table 10: Total Incidence of Breast Cancer in EU4 and the UK (2022-2036)
- Table 11: Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Table 12: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in EU4 and the UK (2022-2036)
- Table 13: Stage-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Table 14: Age-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Table 15: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Table 16: Total Incidence of Breast Cancer in Japan (2022-2036)
- Table 17: Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Table 18: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in Japan (2022-2036)
- Table 19: Stage-specific Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Table 20: Age-specific Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Table 21: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in Japan (2022-2036)
List of Figures
- Figure 1: Molecular Subtypes of Breast Cancer
- Figure 2: Working of Estrogen Receptor
- Figure 3: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.
- Figure 4: ER pathway and mechanisms of resistance
- Figure 5: Metabolism of Estrogen Receptor-Positive Breast Cancer
- Figure 6: Total Incident Cases of Breast Cancer in the 7MM (2022-2036)
- Figure 7: Total Incident Cases of HR+/HER2- Breast Cancer in the 7MM (2022-2036)
- Figure 8: Total Incident Cases of Breast Cancer in the United States (2022-2036)
- Figure 9: Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Figure 10: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in the United States (2022-2036)
- Figure 11: Stage-specific Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Figure 12: Age-specific Incidence of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Figure 13: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in the United States (2022-2036)
- Figure 14: Total Incidence of Breast Cancer in EU4 and the UK (2022-2036)
- Figure 15: Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Figure 16: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in EU4 and the UK (2022-2036)
- Figure 17: Stage-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Figure 18: Age-specific Incidence of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Figure 19: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in EU4 and the UK (2022-2036)
- Figure 20: Total Incidence of Breast Cancer in Japan (2022-2036)
- Figure 21: Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Figure 22: Incidence of HR+/HER2- Breast Cancer Cases by Menopausal Status in Japan (2022-2036)
- Figure 23: Stage-specific Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Figure 24: Age-specific Incidence of HR+/HER2- Breast Cancer in Japan (2022-2036)
- Figure 25: Line-wise Metastatic Cases of HR+/HER2- Breast Cancer in Japan (2022-2036)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.